January 10, 2007
iCo Therapeutics has announced a licensing deal that gives it worldwide rights for the development and commercialization of CAT-213, a treatment for allergic disorders.
From the Vancouver Sun, by Gillian Shaw, an excerpt:
“Vancouver, BC: iCo Therapeutics has announced a licensing deal that gives it worldwide rights for the development and commercialization of CAT-213, a treatment for allergic disorders.
The announcement follows on the heels of the company’s recent announcement that it has filed an investigational new drug application with the U.S. Food and Drug Administration for iCo-007, its experimental treatment for eye diseases including age related macular degeneration and diabetic retinopathy.
And it propels the fledgling biotech into a clinical stage company, an accomplishment that typically takes years and tens of millions of dollars. …”
Read whole PDF article:
Vancouver Sun Jan 2007 iCo Therapeutics Licensing Deal.pdf
About iCo Therapeutics, Inc.
iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology company focused on developing pre-existing drugs for a range of new conditions affecting isolated biological environments – areas such as the eye, spinal cord, or joints – where locally-administered application of these therapies would have minimal systemic distribution and fewer safety issues.
For more information, visit the company website at: https://icotherapeutics.com.
Business Development Contact:
Dr. John Clement, CTO
Mr. John Meekison, CFO